Hermes Medical Solutions Receives 510k Approval for Hybrid3D™ 2.2
Stockholm - November 25th 2017
Hermes Medical Solutions announces the release of Hybrid 3D™, expanding the extensive clinical capabilities within the Hermes Enterprise Molecular Imaging Platform. Hybrid 3D™ is the first-to-market solution for absolute quantification for multi modality fusion and molecular imaging. Hybrid 3D™ empowers clinical decision makers with the ability to view, fuse and quantify molecular imaging with other rich image data from supporting imaging systems. This unique solution continues to enrich Hermes end-to-end clinical workflow for molecular imaging.
Hybrid 3D™ provides absolute quantification at the point of clinical decision in context with imaging workflow platforms. Absolute quantification refers to the ability to quantify SPECT, PET and Hybrid systems regardless of vendor. This allows for consistency, reproducibility and a measurable gain in efficiency. A key feature of Hybrid 3D™ offers users tools for enabling tumor delineation and quantification based on published oncology metrics: WHO, EORTC, qPET, Deauville and RECIST. The key benefit will be reproducibility over multiple time points. Furthermore, Hybrid 3D™ TumorFinder delivers automation for whole-body PET lesion detection with PERCIST response assessment, visual and statistical evaluation of total and individual tumor burden and follow-up on clinical outcome.
Hybrid 3D™ achieves standardization and interoperability across modalities, timepoints and isotopes to deliver uninterrupted clinical workflows. To gain control over the expanding volumes of imaging data used in clinical decisions, Hybrid 3D™ empowers users with a unique data browser, that keeps data organized using data driven intelligence to dynamically group, expand, collapse and filter the data. Hybrid 3D™ provides users the freedom to control visible and fused data in any layout using an intuitive drag and drop from the data browser. Data intelligence driven protocols allow Hybrid 3D™ to automatically adapt and scale it’s UI and layouts with the data. Spend less time configuring and customizing and more time taking clinical decisions.
To learn more about the new Hybrid 3D™ and how Hermes is bringing Innovation for Referring Services and Treatment, visit us at booth #2165 during the RSNA meeting November 26th through December 1st 2017.
About Hermes Medical Solutions
Hermes Medical Solutions holds more than 40 years of recognition for Clinical Excellence and innovation in Molecular Imaging. Hermes delivers Enterprise Class systems and software for integrating, visualizing, processing and archiving imaging data from different imaging modalities and devices within Molecular Imaging and Radiology. Hermes solutions are empowering physicians by enabling a faster and more accurate diagnosis of patients, thereby improving quality and efficiency for healthcare provider’s clinical decision making.
Director Strategic Marketing